News

Cancer Research2d
Trends in Cancer Incidence and Mortality Rates in Early-Onset and Older-Onset Age Groups in the United States, 2010–2019 - American Association for Cancer Research
We estimated age-standardized cancer incidence (2010–2019) and mortality rates (2010–2022) in the United States to investigate whether cancer rates have increased at younger ages. Fourteen cancers had ...
Cancer Research2d
Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity Available to Purchase - American Association for Cancer Research
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous ...
Cancer Research2d
Response and Resistance to RAS Inhibition in Cancer Available to Purchase - American Association for Cancer Research
AbstractRAS inhibition has the potential to transform cancer treatment for many patients. The landscape of RAS inhibitor therapies is rapidly evolving, with two mutant-selective KRAS inhibitors now ...
Cancer Research3d
Paving a Path to Clinical Impact with Radiomics: Enabling Reproducibility and Reach Available to Purchase - American Association for Cancer Research
Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...
Cancer Research3d
Artificial Intelligence–Driven Cancer Diagnostics: Enhancing Radiology and Pathology through Reproducibility, Explainability, and Multimodality - American Association for ...
Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...
Cancer Research3d
Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Available to Purchase - American Association for Cancer Research
Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been ...
Cancer Research2y
Abstract - American Association for Cancer Research
KRAS pathways are frequently upregulated in cancers bearing KRAS mutations or by other signaling modifications. Also, resistance to KRAS G12C inhibitors and other KRAS/RAF/MEK pathway drugs is ...
Cancer Research2mon
Abstract - American Association for Cancer Research
AbstractBackground:. The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and the development of novel treatments, underscoring the need for ...
Cancer Research4d
Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials - American Association for Cancer Research
Abstract. Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In ...
Cancer Research4d
Antibody–Drug Conjugates in Non–Small Cell Lung Cancer: Where Are the Target and the Biomarker? Available to Purchase - American Association for Cancer Research
Summary. Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...
Cancer Research4d
Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study - American Association for ...
Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...
Cancer Research1y
Abstract 3315: Preclinical studies of TSN1611, a potent, selective, and orally bioavailable KRAS G12D inhibitor Free - American Association for Cancer Research
Abstract. Background: KRAS mutations are the most frequently encountered driver oncogene, involved in ~25% of all human cancers [1,2]. KRASG12D is the predominant KRAS mutation isoform, detected in ...